Contact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
Oncology Consortia
Collaboration & Innovation in Cancer Research
The Oncology Consortia of Criterium are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:
Academic GI Cancer Consortium (AGICC)
Academic Myeloma Consortium (AMyC)
Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)
Academic Breast Cancer Consortium (ABRCC)
Academic Urology Research Investigators Consortium (AURIC)
The Consortia Model utilizes translational science methodologies to streamline cancer research and development. Each member chosen for the consortia is usually located at a hospital associated with an academic institution that has superior infrastructure and staff to meet the requirements for not only translational and investigator initiated studies, but also the design and completion of all phases of clinical trials. Our model allows us to provide expertise and innovative solutions for the rapid design, implementation, management and completion of complex cancer trials.
"As we learn more and more about the biology of breast cancer and the body's reaction to its presence, new therapies are being developed at a rapid pace. At ABRCC we are helping to develop new ideas on how to take advantage of these advances -- and utilizing a clinical research infrastructure that provides swift and cost-effective evaluation of these treatments, within a framework of multiple institutions serving a variety of patient populations."
The Academic GI Cancer Consortium (AGICC) is presently represented by Key Opinion Leaders (KOLs) and Top Investigators at 18 of the most prestigious institutions in the USA.
It represents an innovative research model that brings together a world class team of institutions and investigators to design and rapidly complete clinical trials in gastrointestinal (GI) cancers.
"Today, every cancer is a "rare tumor" due to its unique molecular characteristics, requiring teams of experts with the experience and knowledge to tackle these distinct problems. AGICC is up to the challenge, carrying out cutting edge clinical trials and ultimately improving patient outcomes."
The Academic Myeloma Cancer Consortium (AMyC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at 9 of the most prestigious institutions in the USA. It brings together an expert team of institutions and investigators to design and rapidly complete clinical trials with the ultimate goal of identifying new drugs to treat this disease.
"AMyC fills a critical need for pharmaceutical sponsors, providing an unparalleled level of strategic, scientific, and operational expertise in a timely manner."
The Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at 12 of the most prestigious institutions in the USA. Our Centralized Network Model (CNM) advances the clinical trial model to be better suited to adapt to changes in rapid cancer drug development.
"ATOMIC brings together a powerful mixture of mature thought leaders and the next generation of experts with the sole goal of designing and completing clinical trials that will change the way we do business in thoracic oncology for the better."
The Academic Breast Cancer Consortium (ABRCC) is represented by Key Opinion Leaders (KOLs) and Top Investigators at 14 of the most prestigious institutions in the USA. It provides a platform on which to design and develop state of the art targeted and combination studies for cancer drug treatments.
"ABRCC is an academic consortium formed for the new era of clinical trial design and implementation. Our goal is to rapidly translate advances in breast cancer research into targeted therapies that will benefit our patients."
The Academic Urology Research Investigators Consortium (AURIC) is presently represented by Key Opinion Leaders (KOLs) and Top Investigators at the most prestigious institutions in the USA. It represents an innovative research model that brings together a world class team of institutions and investigators to design and rapidly complete clinical trials in GU cancers.
"With AURIC, we have brought together recognized clinical researchers from leading institutions to investigate new drugs and novel combinations to improve the treatment of urologic cancers and to move towards a more personalized treatment approach."
